gentamicin sulfate
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
9200
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
December 13, 2025
Machine-Learning and Gene-Synergy Networks Reveal Interpretable Drivers of Antibiotic Resistance in Staphylococcus aureus.
(PubMed, Int J Antimicrob Agents)
- "Our findings indicate that antibiotic resistance in S. aureus involves distinct genetic network architectures depending on the antibiotic, highlighting the diverse regulatory pathways bacteria employ to acquire resistance. This discovery-oriented framework prioritizes interpretable determinants and generates testable mechanistic hypotheses, with prospective standardized evaluations aimed at assessing its translatability to clinical settings."
Journal
December 13, 2025
Eco-friendly synthesis of silver nanoparticles from the leaf blades extract of seagrass Thalassia hemprichii: Multifunctional agents for biomedical and environmental applications.
(PubMed, J Genet Eng Biotechnol)
- "The antibacterial efficacy of silver nanoparticles was assessed against pathogenic species of Staphylococcus aureus and Escherichia coli reporting inhibitory zones of 13 ± 0.3 and 21 ± 0.2 mm, respectively comparable to the standard Gentamycin (22 ± 0.4 mm). The synthesized AgNPs demonstrated excellent dye degradation kinetics in non-photocatalytic dyes methyl orange (96 %; 30 min) and safranin O (95 %; 40 min) along with experimental reusability found to be satisfactorily upto 7 cycles."
Journal
December 13, 2025
Mechanistic Insights Into Vincamine's Cardio-Protection Against Gentamicin Toxicity: Crosstalk Between Nrf2/HO-1, Klotho, WNT-4/β-Catenin, and pERK/NF-κB Pathways.
(PubMed, J Appl Toxicol)
- "Results demonstrated that VIN significantly reduced GET-induced cardiac damage by modulating crucial signaling pathways and markedly diminished the tissue structural alterations caused by GET. These findings suggest that VIN may serve as a promising cardioprotective agent against GET-induced toxicity through the regulation of pathways including Nrf2/HO-1, pERK/NF-κB, WNT-4/pGSK-3β/β-catenin, and Bax/Bcl-2."
IO biomarker • Journal • Cardiovascular • Infectious Disease • Inflammation • BAX • BCL2 • CTNNB1 • IL6 • TNFA
December 12, 2025
A case report of ulceroglandular tularemia.
(PubMed, Przegl Epidemiol)
- "Physicians in endemic areas are obliged to be aware of a high index of suspicion for tularemia. It should be included in the differential diagnosis when evaluating patients presenting with flu-like symptoms, lymphadenopathy, and non-healing ulcers."
Journal • Pain
November 04, 2025
Evaluating ribosomal readthrough as a precision medicine strategy for restoring factor VIII expression in hemophilia a
(ASH 2025)
- "We testedaminoglycoside antibiotics (gentamicin, G418, ELX02) and non-aminoglycoside agents (ataluren and 2,6-diaminopurine [DAP]), each employing distinct mechanisms to induce ribosomal readthrough. Both aminoglycoside andnon-aminoglycoside compounds can restore partial FVIII expression in a mutation-specific manner. Theseresults support the further development of readthrough-based therapies as a cost-effective andaccessible treatment option for a subset of severe HA patients, potentially reducing their dependence onconventional replacement therapies."
Cystic Fibrosis • Duchenne Muscular Dystrophy • Genetic Disorders • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Muscular Dystrophy • Rare Diseases • Respiratory Diseases
December 12, 2025
PA23 A case of neonatal scabies.
(PubMed, Br J Dermatol)
- "However, subsequent HSV polymerase chain reaction was negative and aciclovir was therefore ceased. Empirical treatment with flucloxacillin and gentamycin was also stopped due to no evidence of ongoing infection...Here we present an immunocompromised neonate who was successfully treated with permethrin 5%. Skin lesions can include erythematous papules, nodules and crusts, and in the absence of positive skin scrapings a careful history and examination of close contacts should lead to the eventual diagnosis."
Journal • Atopic Dermatitis • Critical care • Dermatology • Hepatology • Herpes Simplex • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Septic Shock
December 12, 2025
Recent advances in the biosynthetic pathway and structural modification of gentamicin.
(PubMed, Front Microbiol)
- "Finally, this review offers perspectives on the future research directions and uses of gentamicin. In summary, a detailed dissection of the complex biosynthetic network of gentamicin is provided to lay the groundwork for targeted and random structural modifications of gentamicin using combinatorial biosynthetic and high-throughput screening technologies to develop new aminoglycoside antibiotics with lower host toxicity and greater activity against resistant strains."
Journal • Review • Infectious Disease
December 12, 2025
GD04 (P064) A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
Prosthetic joint infections in shoulder and elbow: An evaluation of micro-organisms in periprosthetic shoulder and elbow joint infections across the United Kingdom.
(PubMed, Shoulder Elbow)
- "Teicoplanin with gentamicin was the most used peri-operative anti-microbial protocol (35%). CNS, C. acnes and MSSA were common in shoulder PJI and CNS and MSSA in elbow PJI. Peri-operative antibiotic protocols and intra-operative sampling methods varied."
Journal • Infectious Disease • Orthopedics
December 12, 2025
SG07 Real-world experience with the use of intravenous gentamicin to induce nonsense mutation readthrough in an adult patient with recessive dystrophic epidermolysis bullosa.
(PubMed, Br J Dermatol)
- "IV gentamicin may be a safe, efficacious, low-cost and readily available treatment for patients with RDEB. Further real-world practice is necessary to optimize the dosing schedule and evaluate longer term outcomes on wound closure and quality of life, in a larger patient population."
Journal • Real-world evidence • Genetic Disorders • Pain • COL7A1
December 12, 2025
P064 A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
Effects of antibiotic treatments on symbiotic bacteria and life history traits of Bemisia tabaci and Trialeurodes vaporariorum (Hemiptera: Aleyrodidae): implications for pest control strategies.
(PubMed, J Econ Entomol)
- "The antibiotic treatments-tetracycline, rifampicin, and a cocktail of ampicillin, cefotaxime, and gentamicin-significantly altered the abundance of specific symbionts, with notable reductions of Rickettsia in B. tabaci and Arsenophonus in T. vaporariorum. A negative r value was also recorded in B. tabaci following tetracycline treatment. These results highlight the critical role of symbiotic bacteria in whitefly biology and provide insight into the potential consequences of disrupting these associations."
Journal
December 11, 2025
Combining Bile Salt with Gentamicin: A Promising Strategy Against Vibrio Parahaemolyticus and Escherichia Coli.
(PubMed, Curr Microbiol)
- "Therefore, the combination of bile salts and GEN triggered severe intracellular oxidative damage and irreversible cell membrane disruption, ultimately leading to bacterial death. The synergistic effect between bile salts and GEN offers a promising strategy for the treatment of foodborne pathogens."
Journal • Infectious Disease
December 11, 2025
Assessment of a Novel Synbitotic of Pomegranate Peels Extract and Multi-Specie Probiotics as an Antibiotics Alternative in Ruminants.
(PubMed, Probiotics Antimicrob Proteins)
- "NPLYS showed antimicrobial activity against Escherichia (E.) coli and Staphylococcus (Staph.) aureus similar to gentamicin, while FPLYS showed lower activity (p < 0.05)...The synbiotic developed in this study can be either used as an antimicrobial agent and/or a rumen fermentation modifier, replacing synthetic antibiotics used for these purposes. Nanoencapsulation process improved biological activities of the synbiotic."
Journal
December 11, 2025
From Structure to Function: 2-Chloro-5-nitrobenzoic Acid Derivatives as Potential Next-Generation Antibacterials.
(PubMed, Int J Mol Sci)
- "Antibacterial assays demonstrated that compound 1 exhibited a broad inhibitory profile against both Gram-positive and Gram-negative bacteria. In contrast, compound 2 exhibited selective inhibition against methicillin-resistant Staphylococcus aureus (MRSA) comparable to that of gentamicin."
Journal • Infectious Disease
December 11, 2025
Prevalence and Antimicrobial Resistance Patterns of Salmonella in Asymptomatic Horses in Eastern Spain: A One Health Perspective.
(PubMed, Animals (Basel))
- "The highest resistance rates were against sulfamethoxazole and gentamicin, followed by ciprofloxacin and tigecycline. (4) Healthy horses can act as silent carriers of multidrug-resistant Salmonella, highlighting the need for surveillance, strengthened biosecurity, and prudent antimicrobial use within a One Health framework."
Journal
December 11, 2025
Molecular Epidemiology and Antibiotic Resistance of Sheep-Derived Mannheimia haemolytica in Northwestern China.
(PubMed, Animals (Basel))
- "Antibiotic susceptibility testing showed sensitivity to ciprofloxacin, azithromycin, gentamicin, and levofloxacin, while resistance was observed for tiamulin and enrofloxacin. These findings indicate a high prevalence and strong pathogenicity of ovine M. haemolytica in Shaanxi, underscore the presence of key resistance traits, and provide a genomic and pathogenic reference to guide region-specific surveillance, therapeutic decisions, and vaccine-oriented control in small ruminant herds. Importantly, these results highlight the need for region-specific monitoring and judicious antibiotic use, which are essential to forestall the spread of resistant strains and to ensure sustainable disease management strategies."
Journal • Respiratory Diseases
December 11, 2025
Secretory Leukocyte Protease Inhibitor: A Pleiotropic Molecule for the Potential Diagnosis of and Therapy for Acute Kidney Injury.
(PubMed, Int J Mol Sci)
- "Preclinical studies demonstrate that administration of recombinant SLPI ameliorates renal dysfunction in multiple AKI models, including ischemia-reperfusion injury and nephrotoxic models induced by gentamicin or cisplatin. Furthermore, the antifibrotic properties of SLPI underscore its therapeutic potential in halting AKI progression to chronic kidney disease. By integrating available evidence, this review aims to elucidate that, as an early acute-phase response molecule, SLPI serves dual roles as not only an early diagnostic and prognostic biomarker for AKI, but also a renoprotective molecule countering kidney injury."
Biomarker • Journal • Review • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Reperfusion Injury • Transplantation
December 11, 2025
Genomic insights and molecular epidemiology through whole genome sequencing in clinical Serratia marcescens ST-367 isolated from the Kingdom of Bahrain.
(PubMed, J Infect Public Health)
- "To our knowledge, this is the first report of S. marcescens ST-367 in the Gulf Cooperation Council. The genetic diversity and mechanisms of virulence and antibiotic resistance in this isolate shed light on the evolution of high-risk isolates. Additionally, this will serve as a foundation for future extensively drug-resistant isolates."
Journal • Gene Therapies • Infectious Disease
December 10, 2025
Effect of surgical antimicrobial prophylaxis duration for colic surgery on complications and resistome.
(PubMed, Equine Vet J)
- "SAP for 24-h is recommended for horses undergoing colic surgery."
Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease
December 10, 2025
Research of antimicrobial resistance and its associated genes distribution in Escherichia coli from diarrheic calves in the Ulagai region of China.
(PubMed, Front Vet Sci)
- "They were resistant to bacitracin, and 82% were resistant to gentamicin...All strains isolated from diarrheic calves exhibited multidrug resistance and carried numerous resistance genes. Furthermore, the observation of abundant mobile genetic elements in the strains increases the risk of horizontal gene transfer of resistance genes, indicating the severity of issues faced by clinical prevention and control measures."
Journal • Gene Therapies
December 10, 2025
Peritoneal Dialysis-Associated Peritonitis Caused by Lautropia Mirabilis and Concurrent Viral Infection: A Case Report.
(PubMed, Case Rep Nephrol Dial)
- "Therapy with intravenous moxifloxacin, intraperitoneal gentamicin, and oral ganciclovir led to rapid WBC decline and clinical improvement within 48 h. After 1 week of inpatient monitoring, the patient was discharged with a 2-week course of oral moxifloxacin. Culture-negative PDAP often necessitates empirical antibiotic therapy, carrying a high risk of failure and increased healthcare costs. This case suggests that tNGS could be used as a complementary diagnostic tool in selected cases of refractory, culture-negative PDAP, potentially aiding the identification of pathogens and guiding therapy."
Journal • Chronic Kidney Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Infectious Disease • Nephrology • Polycystic Kidney Disease • Renal Disease
December 09, 2025
Impact of Plant Growth Promoting Rhizobacteria Exiguobacterium Acetylicum RGK and Enterobacter Mori RGK1 on Growth Parameters and Phytochemicals of Asparagus Racemosus.
(PubMed, Curr Microbiol)
- "Additionally, has shown antibiotic susceptibility to antibiotics such as Amikacin, Netilin, Co-trimaxazole, Streptomycin, Furazolidone, Kanamycin, Nalidixic acid, Nitrofurantoin, Tobramycin, Oxytetracyclin, Chloramphenicol, Gentamycin and their ability to withstand salt concentration (NaCl) up to 5-6%. As compared to the untreated plants, PGPR-treated plantlets showed higher amounts of secondary metabolites, primarily Diosgenin. The main focus is on the use of multiple microbial strains in a single formulation, an emerging trend in sustainable agriculture."
Journal
December 09, 2025
Infective Endocarditis Caused by Serratia marcescens: A Case Report and Literature Review.
(PubMed, Cureus)
- "We report the case of a middle-aged male with a significant past medical history of atrial fibrillation managed with warfarin and mitral valve replacement for rheumatic mitral stenosis. The patient was treated with a combination of intravenous meropenem and gentamicin for a total of four weeks. Follow-up TEE demonstrated complete resolution of the vegetation, and the patient had an uneventful recovery."
Journal • Atrial Fibrillation • Cardiovascular • CNS Disorders • Hypotension • Infectious Disease • Septic Shock
December 09, 2025
ADOPT GG: Antibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin.
(clinicaltrials.gov)
- P=N/A | N=139 | Not yet recruiting | Sponsor: Biocomposites Ltd
New trial • Inflammation
1 to 25
Of
9200
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368